AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10902536 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (250g curd, 150g yoghurt, 3 slices pineapple, 2 breakfast rolls, 2 cups of coffee, 10g coffee cream, 20g butter, 50g jam, 20g honey; 580mg Ca)
Number of subjects: 8
Study 10902536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactogluconate effervescent tablet (500mg Ca)
Number of subjects: 8
Study 7595245 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic similarity (e.g., keller‐KELLER, cellar‐ladle)
Number of subjects: 0
Study 7595245 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological relatedness (e.g., kellen‐KELLE, ladles‐ladle)
Number of subjects: 0
Study 7595245 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological similarity
Number of subjects: 0
Study 7595245 — intervention group
Group type: EXPERIMENTAL
Intervention: Form similarity
Number of subjects: 0
Study 1487608 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms
Number of subjects: 48
Study 1487608 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin 0.4 U/min for 24 h
Number of subjects: 48
Study 1487608 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 48
Study 1487608 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 48
Study 1487608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality related to bleeding esophageal varices
Number of subjects: 48
Study 3711379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 8‐methoxypsoralen
Number of subjects: 40
Study 3711379 — intervention group
Group type: COMPARATOR
Intervention: Bath-water delivery of 8‐methoxypsoralen
Number of subjects: 40
Study 31635021 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A treatment for chronic migraine
Number of subjects: 0
Study 31635021 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study 29944925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 29944925 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 40
Study 27390050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oppanol® PIB‐containing transdermal therapeutic system (TTS) formulation (0.3 mg clonidine/24 h)
Number of subjects: 58
Study 27390050 — intervention group
Group type: COMPARATOR
Intervention: All patch types (T1/R1, R1/T1, T2, R2)
Number of subjects: 58
Study 24509969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical scar gel containing extract of Allium cepae, allantoin, and heparin (Contractubex) applied twice daily
Number of subjects: 61
Study 24509969 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study 21689142 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg for 10 days
Number of subjects: 90
Study 21689142 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg for 10 days
Number of subjects: 90
Study 19733106 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.2mg/kg (group 1)
Number of subjects: 16
Study 19733106 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.4mg/kg (group 2)
Number of subjects: 16
Study 18467080 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin
Number of subjects: 0
Study 18467080 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-doxorubicin-cisplatin
Number of subjects: 0
Study 18467080 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin
Number of subjects: 0
Study 18467080 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-doxorubicin-cisplatin
Number of subjects: 0
Study 18467080 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy plus chemotherapy
Number of subjects: 0
Study 15888514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (n = 18)
Number of subjects: 24
Study 15888514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 24
Study 12742999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 655
Study 12742999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 9881785 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial trephine procedure
Number of subjects: 30
Study 9881785 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest harvesting
Number of subjects: 30
Study 7844217 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (50 mg/day for 5 days) and IUI (clomiphene/IUI group)
Number of subjects: 100
Study 7844217 — intervention group
Group type: EXPERIMENTAL
Intervention: Late low-dose pure follicle stimulating hormone (FSH, 75 IU/day from day cycle 7 until the leading follicle reached > 17 mm in diameter) and IUI (FSH/IUI group)
Number of subjects: 100
Study 3395259 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa 50/200 (SINEMET CR)
Number of subjects: 21
Study 3395259 — intervention group
Group type: COMPARATOR
Intervention: Standard carbidopa/levodopa (SINEMET 25/100)
Number of subjects: 21
Study 31506853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in addition to standard medical care
Number of subjects: 70
Study 31506853 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only
Number of subjects: 70
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 92
Study 29907085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29907085 — intervention group
Group type: COMPARATOR
Intervention: Melatonin or Placebo (during withdrawal)
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular BZDA users
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular BZDA users
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-users
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular users
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users
Number of subjects: 92
Study 29907085 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 92
Study 28651701 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2g/day for 26 weeks
Number of subjects: 71
Study 28651701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26132687 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine plus exposure therapy (n = 20)
Number of subjects: 36
Study 26132687 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exposure therapy (n = 16)
Number of subjects: 36
Study 26132687 — intervention group
Group type: COMPARATOR
Intervention: Both groups (D-Cycloserine and placebo)
Number of subjects: 36
Study 24133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day for 6-10 months)
Number of subjects: 34
Study 24133627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 34
Study 21367625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg three times a day (titrated to 100 mg after one month)
Number of subjects: 0
Study 21367625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21367625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 18326618 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE), 890 mg polyphenols and 366 mg EGCG, taken as 3 capsules before exercise
Number of subjects: 23
Study 18326618 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 23
Study 18326618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn-flour)
Number of subjects: 23
Study 16508253 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 199
Study 16508253 — intervention group
Group type: COMPARATOR
Intervention: Lipovenoes 20% (Control)
Number of subjects: 199
Study 12716269 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (individually tailored remedy)
Number of subjects: 44
Study 12716269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10715299 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methotrexate (MTX) 1,000 mg/m2 plus IV mercaptopurine (MP) 1,000 mg/m2 (regimen A)
Number of subjects: 651
Study 10715299 — intervention group
Group type: COMPARATOR
Intervention: IV methotrexate (MTX) 1,000 mg/m2 alone (regimen C)
Number of subjects: 651
Study 10715299 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (A and C)
Number of subjects: 651
Study 9088362 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advisory letter
Number of subjects: 28000
Study 9088362 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-sell advisory letter
Number of subjects: 28000
Study 9088362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letter)
Number of subjects: 28000
Study 9088362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both letters (standard and soft-sell)
Number of subjects: 28000
Study 8330937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cermet ionomer cement with varnish
Number of subjects: 54
Study 8330937 — intervention group
Group type: COMPARATOR
Intervention: Amalgam with cavity varnish
Number of subjects: 54
Study 8330937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cermet ionomer cement without varnish
Number of subjects: 54
Study 2941771 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 2941771 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 2941771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28508559 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 90 gCHO hour-1)
Number of subjects: 18
Study 28508559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, 0 gCHO hour-1)
Number of subjects: 18
Study 26716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages for adherence for 21 days plus usual care
Number of subjects: 75
Study 26716365 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 24556879 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable hydrophilic acrylic IOL through a 2.5‐mm corneal incision
Number of subjects: 1200
Study 24556879 — intervention group
Group type: COMPARATOR
Intervention: Rigid PMMA IOL via a 5‐mm sclerocorneal tunnel
Number of subjects: 1200
Study 23299530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg with mFOLFOX6
Number of subjects: 210
Study 23299530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg with mFOLFOX6
Number of subjects: 210
Study 23299530 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab with mFOLFOX6
Number of subjects: 210
Study 23299530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg
Number of subjects: 210
Study 23299530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg
Number of subjects: 210
Study 23299530 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 210
Study 19900491 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (450 nmol subcutaneous)
Number of subjects: 10
Study 19900491 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 10
Study 17901967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric conditions
Number of subjects: 75
Study 17901967 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid conditions
Number of subjects: 75
Study 17901967 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric conditions
Number of subjects: 75
Study 17901967 — intervention group
Group type: COMPARATOR
Intervention: Relatively dry conditions
Number of subjects: 75
Study 15935648 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine spray (0.5% in alcoholic solution)
Number of subjects: 100
Study 15935648 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine sachet (0.05% aqueous solution)
Number of subjects: 100
Study 12930191 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 g EGb 761
Number of subjects: 20
Study 10616614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 10616614 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 8914119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (tryptophan deficient amino acid mixture)
Number of subjects: 0
Study 8914119 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid mixture containing tryptophan (control)
Number of subjects: 0
Study 1860302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine pretreatment (five 150-mg oral doses given every 12 hours)
Number of subjects: 12
Study 1860302 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine pretreatment (control)
Number of subjects: 12
Study 1860302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine pretreatment
Number of subjects: 12
Study 7334938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 2 mg of micronized oestradiol and 1 mg of micronized oestriol (Estrofem)
Number of subjects: 10
Study 7334938 — intervention group
Group type: COMPARATOR
Intervention: Aqueous suspension of the same micronized hormones
Number of subjects: 10
Study 30977122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventriculo-amniotic shunting
Number of subjects: 44
Study 28625387 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital influenza vaccination
Number of subjects: 4400
Study 28625387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4400
Study 26764121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 30 mg administered every 7 days (Q7D)
Number of subjects: 23
Study 26764121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 30 mg administered every 5 days (Q5D)
Number of subjects: 23
Study 26764121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 30 mg
Number of subjects: 23
Study 24796046 — intervention group
Group type: COMPARATOR
Intervention: CC + Zhangmo decoction group (C)
Number of subjects: 160
Study 24796046 — intervention group
Group type: COMPARATOR
Intervention: CC + Zhangmo decoction + warm needling group (D)
Number of subjects: 160
Study 24796046 — intervention group
Group type: COMPARATOR
Intervention: CC + progynova group (B)
Number of subjects: 160
Study 21254195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean USS
Number of subjects: 1063
Study 21254195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum USS
Number of subjects: 1063
Study 21254195 — intervention group
Group type: EXPERIMENTAL
Intervention: USS scores
Number of subjects: 1063
Study 18815997 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week integrated treatment targeting anger and addictions (i.e., both gambling and substance use)
Number of subjects: 42
Study 18815997 — intervention group
Group type: COMPARATOR
Intervention: Specialized treatment-as-usual (TAU) for gambling and substance use
Number of subjects: 42
Study 17189398 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sorafenib twice daily plus best supportive care
Number of subjects: 902
Study 17189398 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 902
Study 17189398 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sorafenib twice daily
Number of subjects: 902
Study 12602772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank tests for clustered survival data (logrank and Wilcoxon tests)
Number of subjects: 0
Study 12602772 — intervention group
Group type: COMPARATOR
Intervention: Standard rank tests for independent survival data
Number of subjects: 0
Study 11025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 or 8 mg once daily
Number of subjects: 795
Study 11025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard 1 mg to 8 mg once daily
Number of subjects: 795
Study 11025377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study 11025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 795
Study 11025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard
Number of subjects: 795
Study 11025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and Doxazosin standard
Number of subjects: 795
Study 8765624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (6 mg/kg per week)
Number of subjects: 42
Study 8765624 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous lactate (elemental iron, 12 mg/kg per day)
Number of subjects: 42
Study 1576562 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 140
Study 1576562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 4016494 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal lymphoscintigraphy
Number of subjects: 32
Study 4016494 — intervention group
Group type: COMPARATOR
Intervention: Lymphography
Number of subjects: 32
Study 30867553 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the supero-lateral branch of the medial forebrain bundle (slMFB)
Number of subjects: 16
Study 30867553 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 28642209 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral naltrexone (50mg)
Number of subjects: 17
Study 28642209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26138865 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg BID
Number of subjects: 16
Study 26138865 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin 10 mg QD
Number of subjects: 16
Study 23439620 — intervention group
Group type: EXPERIMENTAL
Intervention: High socioeconomic status
Number of subjects: 375
Study 23439620 — intervention group
Group type: COMPARATOR
Intervention: Low socioeconomic status
Number of subjects: 375
Study 23439620 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chronic health conditions
Number of subjects: 375
Study 23439620 — intervention group
Group type: COMPARATOR
Intervention: Absence of chronic health conditions
Number of subjects: 375
Study 21482091 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 μg of tiotropium bromide plus 200 μg salbutamol
Number of subjects: 17
Study 21482091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19197768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Plus (ESP)
Number of subjects: 298
Study 19197768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start (ES)
Number of subjects: 298
Study 19197768 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated alcohol users)
Number of subjects: 298
Study 16999641 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 20
Study 12919709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic therapy with etidronate (400 mg/day for 2 weeks followed by 500 mg/day of calcium lactate for 12 weeks, repeated every 14 weeks)
Number of subjects: 52
Study 12919709 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 52
Study 11006672 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured methadone maintenance protocol introduced in general practice.
Number of subjects: 54
Study 11006672 — intervention group
Group type: COMPARATOR
Intervention: Before the introduction of structured methadone maintenance.
Number of subjects: 54
Study 9344053 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiration monitoring during feeding
Number of subjects: 28
Study 9344053 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy with simultaneous respiration monitoring
Number of subjects: 28
Study 1438625 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 19
Study 1438625 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 19
Study 3824375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily after breakfast and at bedtime
Number of subjects: 0
Study 3824375 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg four times daily
Number of subjects: 0
Study 31515625 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy via gasless unilateral axillary approach
Number of subjects: 100
Study 31515625 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy via postauricular facelift approach
Number of subjects: 100
Study 31515625 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcervical thyroidectomy
Number of subjects: 100
Study 30425104 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF23
Number of subjects: 2486
Study 26433135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice services received over a four week period
Number of subjects: 0
Study 24246819 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention aimed at decreasing sugar-sweetened beverage consumption over 6 months
Number of subjects: 0
Study 24246819 — intervention group
Group type: COMPARATOR
Intervention: MoveMore control group focused on physical activity promotion
Number of subjects: 0
Study 22212173 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 0
Study 22212173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment depressive symptoms
Number of subjects: 1726
Study 20105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment depressive symptoms
Number of subjects: 1726
Study 18703607 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scans in group A
Number of subjects: 191
Study 18703607 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scans in group B
Number of subjects: 191